Clinical Trial Update: Reversal of the Anti-platelet Effects of Ticagrelor [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluated reversal of ticagrelor's antiplatelet effects in patients with coronary artery disease and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• TICAGRELOR (ticagrelor)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Coronary Artery Disease | Phase 4 | Status: COMPLETED